Retatrutide vs Survodutide: Triple vs Dual Agonist Research Comparison (UAE 2026)

Why These Two Peptides Are Compared

Retatrutide and survodutide are the headline-grabbing "next generation" incretin peptides — both stretch beyond the GLP-1-only architecture of semaglutide and the GLP-1/GIP dual architecture of tirzepatide. Each adds glucagon receptor agonism to the GLP-1 backbone, which drives hepatic energy expenditure, lipolysis, and direct effects on liver fat. The two compounds diverge on one critical axis: retatrutide also hits GIP, survodutide does not.

For UAE researchers running comparative protocols, that single mechanistic difference reshapes which compound suits which research question. Below we walk through receptor pharmacology, the two pivotal Phase 2 readouts (Jastreboff 2023 and Sanyal 2024), tolerability profiles, and how to source Retatrutide in the UAE with 24h delivery from REVIVE Lab's Dubai stock.

Receptor Pharmacology — The Mechanism Split

Retatrutide (LY3437943) — Triple Agonist

Eli Lilly's retatrutide is a 39-amino-acid peptide engineered to activate three receptors at calibrated potencies. Coskun and colleagues (2022, Cell Metabolism) published the molecular profiling: full-agonist activity at GLP-1R, GIPR, and GCGR, with relative potencies tuned to avoid glucagon-driven hyperglycaemia. The GIP arm adds appetite control via central CNS pathways and improves lipid handling. The glucagon arm drives hepatic fat oxidation and energy expenditure. Together they produce the steepest weight-loss curve in the incretin class to date.

Survodutide (BI 456906) — Dual Agonist

Boehringer Ingelheim and Zealand Pharma co-developed survodutide as a long-acting dual GLP-1/glucagon receptor agonist. No GIP component. The compound is biased toward the glucagon receptor relative to natural glucagon, which concentrates effect on hepatic substrates — directly relevant to MASLD/MASH research. Le Roux and colleagues (2024, Lancet) confirmed the dual-agonist signature in early Phase 2 obesity data; the glucagon arm carries proportionally more of the metabolic effect than in retatrutide.

Head-to-Head: Receptor & Clinical Comparison Table

The Jastreboff 2023 Retatrutide Readout (Weight Loss)

Jastreboff and colleagues published the retatrutide Phase 2 in the New England Journal of Medicine in 2023 (NEJM 389:514–526). 338 adults with obesity, no diabetes, randomised across 1, 4, 8, and 12 mg target doses plus placebo. The 48-week mean weight change percentages were:

• Placebo: −2.1%
• 1 mg: −8.7%
• 4 mg: −17.5%
• 8 mg: −22.8%
• 12 mg: −24.2%

The 12 mg curve had not plateaued at 48 weeks — implying the ceiling effect lies further out. No comparable incretin Phase 2 has shown a steeper trajectory. The Phase 2 diabetes data (Rosenstock 2023, Lancet) added the metabolic case: HbA1c down 2.02% at 12 mg, and an unusual signal — body weight reductions in T2D subjects of 16.94% vs 3.0% for dulaglutide, in the same trial.

The Sanyal 2024 Survodutide Readout (MASH)

Sanyal and colleagues published the survodutide MASH Phase 2 in the New England Journal of Medicine in 2024 (NEJM 391:311–319). 295 adults with biopsy-confirmed MASH (formerly NASH) and fibrosis F1–F3, randomised across 2.4 mg, 4.8 mg, and 6.0 mg target doses plus placebo, 48 weeks.

Primary endpoint — MASH resolution without worsening of fibrosis — was achieved in:

• Placebo: 14%
• 2.4 mg: 47%
• 4.8 mg: 62%
• 6.0 mg: 43% (likely reflects tolerability dropouts)

Improvement in fibrosis by at least one stage occurred in 34–36% of survodutide arms vs 22% placebo. Liver-fat content fell more than 30% in roughly two-thirds of treated subjects. This is the strongest histology-confirmed MASH dataset in the GLP-1/glucagon class to date.

Which Research Question Favours Which Peptide?

Use Retatrutide When the Endpoint Is...

• Body composition / weight loss magnitude. No incretin in clinical development has matched the 24% at 48 weeks trajectory.
• Diabetes + obesity combined endpoints. Triple-agonist HbA1c data is best-in-class.
• Lipid panel improvement. GIP plus glucagon together exert the largest triglyceride and LDL effects observed in incretin research.
• Long-duration tolerability research at moderate doses (4 mg arm sits in the tirzepatide effect range with similar GI profile).

Use Survodutide When the Endpoint Is...

• MASH / MASLD histology endpoints. Sanyal 2024 is the deepest dataset.
• Liver-fat reduction by MRI-PDFF. Greater than 30% reduction in two-thirds of treated subjects.
• Fibrosis stage improvement as a secondary endpoint, in non-cirrhotic populations.
• Glucagon-receptor-isolated research where you want to study the dual pathway without GIP confounding.

Tolerability Profile — Where They Diverge

Both compounds produce the expected GLP-1 class GI side-effect cluster: nausea, vomiting, diarrhoea, constipation, decreased appetite. Severity is dose-dependent and largely titration-dependent.

Retatrutide-specific signals include a modest resting heart rate elevation (6–8 bpm at 12 mg in Jastreboff 2023), proportional to dose. The GIP component may contribute to this. Survodutide-specific signals are weighted toward GI events at upper doses — the 6.0 mg arm in Sanyal 2024 had more discontinuations than the 4.8 mg arm, despite a lower MASH-resolution rate, suggesting tolerability ceiling around 4.8 mg.

For practical titration of retatrutide, see our Retatrutide titration schedule UAE and GLP-1 nausea mitigation guides.

UAE Delivery & Sourcing — Where to Buy Retatrutide in the UAE

REVIVE Lab is a Dubai-based research-peptide supplier with stocked inventory of Retatrutide 5 mg and 10 mg vials. Survodutide is available only to select research clients on request — for most UAE protocols, retatrutide is the more practical comparator because it is in-stock and ships within 24 hours.

24h Delivery Coverage Across the UAE

• Dubai: Same-day delivery on orders confirmed before 14:00 GST. Cold-chain courier 4–8 hour window.
• Abu Dhabi: Next-day cold-chain delivery, often same-day for early morning orders.
• Sharjah, Ajman, Umm Al Quwain: Next-day, cold-chain insulated packaging.
• Ras Al Khaimah, Fujairah: 24–48h cold-chain courier.
• Al Ain & remote zones: Standard 48h delivery with extended ice-pack packaging.

Cold-Chain Logistics

Both retatrutide and survodutide are lyophilised peptides that tolerate brief ambient transit but require refrigeration on arrival. REVIVE ships in foam-insulated parcels with phase-change ice packs validated to hold under 8°C for 36 hours — sufficient even for the harsher UAE summer transit windows. See our UAE peptide storage guide for receiving protocol.

Ordering Process

1. Select Retatrutide 5 mg or 10 mg at the retatrutide product page.
2. Confirm UAE delivery address at checkout — cash on delivery available across all seven emirates.
3. HPLC certificate of analysis emailed at dispatch.
4. Cold-chain courier delivers within the windows above. Immediate refrigeration on arrival.

Cross-Reading the Two Datasets

If you are designing a research protocol that asks "which compound do I run?", the question collapses to: which endpoint matters more — body composition or liver histology? Retatrutide's triple-agonist architecture pushes weight loss further than any peptide currently in clinical development; survodutide's dual architecture, biased toward glucagon, makes it the cleaner tool for hepatic-fat and MASH histology work.

A reasonable interpretation of the published data: the GIP arm on retatrutide adds CNS appetite control and lipid handling that push body-composition endpoints, while survodutide's glucagon-weighted pharmacology concentrates effect on the liver-fat compartment. Neither compound is "better" — they answer different research questions.

For background on the broader incretin class, see Semaglutide vs Retatrutide UAE and Retatrutide vs Mounjaro direct comparison. For our full UAE catalogue, visit peptides UAE.

Practical Notes for UAE Researchers

• Retatrutide is stocked at REVIVE Lab Dubai; 5 mg and 10 mg lyophilised vials with HPLC certificates.
• Survodutide is research-grade only and not held in routine inventory — lead-time 2–3 weeks if available.
• For comparative protocols, the practical recommendation is retatrutide as the primary arm with literature-based survodutide as a reference comparator.
• Storage: Both peptides refrigerated 2–8°C lyophilised; 28 days reconstituted; do not freeze reconstituted vials.
• Reconstitution: See our retatrutide reconstitution math guide for vial math.